Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Bryan Dirks

Showing results (21-30 of 36) with videos related to

Pageof 4
Sort By:
Advances in Therapy|May 18, 2013
Efficacy and safety of lisdexamfetamine dimesylate in children with attention-deficit/hyperactivity disorder and recent methylphenidate useRakesh Jain, Thomas Babcock, Teodor Burtea, et al.
Clinical Pharmacology in Drug Development|March 7, 2023
Exposure-response Modeling From the CLARITY Trial of Pimavanserin for Adjunctive Treatment of Major Depressive DisorderMona Darwish, Bryan Dirks, Julie Passarell, et al.
The Journal of Clinical Psychiatry|August 16, 2013
Lisdexamfetamine dimesylate in adults with attention-deficit/ hyperactivity disorder who report clinically significant impairment in executive function: results from a randomized, double-blind, placebo-controlled studyLenard A Adler, Bryan Dirks, Patrick F Deas, et al.
Neuropsychiatric Disease and Treatment|December 24, 2013
Analysis of individual items on the attention-deficit/hyperactivity disorder symptom rating scale in children and adults: the effects of age and sex in pivotal trials of lisdexamfetamine dimesylateRichard H Weisler, Lenard A Adler, Scott H Kollins, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|December 26, 2025
Drug DevelopmentBryan Dirks, Samantha M Friend, Becky M Howell, et al.
Journal of Attention Disorders|February 15, 2013
ADHD Symptom Rebound and Emotional Lability With Lisdexamfetamine Dimesylate in Children Aged 6 to 12 YearsFrank A López, Ann Childress, Ben Adeyi, et al.
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology|June 13, 2013
Adjunctive lisdexamfetamine dimesylate therapy in adult outpatients with predominant negative symptoms of schizophrenia: open-label and randomized-withdrawal phasesRobert A Lasser, Bryan Dirks, Henry Nasrallah, et al.
BMC Psychiatry|January 30, 2013
Clinical response and symptomatic remission in short- and long-term trials of lisdexamfetamine dimesylate in adults with attention-deficit/hyperactivity disorderGreg W Mattingly, Richard H Weisler, Joel Young, et al.
Journal of Attention Disorders|December 22, 2010
Clinically relevant changes in emotional expression in children with ADHD treated with lisdexamfetamine dimesylateAlain Katic, Lawrence Ginsberg, Rakesh Jain, et al.
The American Journal of Psychiatry|May 5, 2009
Randomized, double-blind, placebo-controlled study of paliperidone extended-release and quetiapine in inpatients with recently exacerbated schizophreniaCarla M Canuso, Bryan Dirks, Jennifer Carothers, et al.
Pageof 4

Showing results (21-30 of 36) with videos related to

Sort By:
Pageof 4
Advances in Therapy|May 18, 2013
Efficacy and safety of lisdexamfetamine dimesylate in children with attention-deficit/hyperactivity disorder and recent methylphenidate useRakesh Jain, Thomas Babcock, Teodor Burtea, et al.
Clinical Pharmacology in Drug Development|March 7, 2023
Exposure-response Modeling From the CLARITY Trial of Pimavanserin for Adjunctive Treatment of Major Depressive DisorderMona Darwish, Bryan Dirks, Julie Passarell, et al.
The Journal of Clinical Psychiatry|August 16, 2013
Lisdexamfetamine dimesylate in adults with attention-deficit/ hyperactivity disorder who report clinically significant impairment in executive function: results from a randomized, double-blind, placebo-controlled studyLenard A Adler, Bryan Dirks, Patrick F Deas, et al.
Neuropsychiatric Disease and Treatment|December 24, 2013
Analysis of individual items on the attention-deficit/hyperactivity disorder symptom rating scale in children and adults: the effects of age and sex in pivotal trials of lisdexamfetamine dimesylateRichard H Weisler, Lenard A Adler, Scott H Kollins, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|December 26, 2025
Drug DevelopmentBryan Dirks, Samantha M Friend, Becky M Howell, et al.
Journal of Attention Disorders|February 15, 2013
ADHD Symptom Rebound and Emotional Lability With Lisdexamfetamine Dimesylate in Children Aged 6 to 12 YearsFrank A López, Ann Childress, Ben Adeyi, et al.
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology|June 13, 2013
Adjunctive lisdexamfetamine dimesylate therapy in adult outpatients with predominant negative symptoms of schizophrenia: open-label and randomized-withdrawal phasesRobert A Lasser, Bryan Dirks, Henry Nasrallah, et al.
BMC Psychiatry|January 30, 2013
Clinical response and symptomatic remission in short- and long-term trials of lisdexamfetamine dimesylate in adults with attention-deficit/hyperactivity disorderGreg W Mattingly, Richard H Weisler, Joel Young, et al.
Journal of Attention Disorders|December 22, 2010
Clinically relevant changes in emotional expression in children with ADHD treated with lisdexamfetamine dimesylateAlain Katic, Lawrence Ginsberg, Rakesh Jain, et al.
The American Journal of Psychiatry|May 5, 2009
Randomized, double-blind, placebo-controlled study of paliperidone extended-release and quetiapine in inpatients with recently exacerbated schizophreniaCarla M Canuso, Bryan Dirks, Jennifer Carothers, et al.
Pageof 4